The company’s study included 74 participants with mild to moderate Alzheimer’s who received either the Cognito stimulation or a sham device that acted as a placebo. Subjects were asked to use the headset for an hour every day for six months. Compared with the placebo group, those who got the Cognito stimulation showed a 77 […]
Read MoreNearly 30 years ago, when the first effective Alzheimer’s drugs were approved, optimism was in the air. True, the drugs didn’t slow the underlying disease, but they made a meaningful difference to symptoms. It seemed like disease-modifying drugs would be coming any day. “The story was, within a few years, we should have drugs that will […]
Read MoreHundreds of millions of people worldwide suffer from Alzheimer’s and mental health conditions such as depression and anxiety, but these are still underdiagnosed or detected too late for optimal intervention. Startup Accexible is trying to change that, based on the premise that early signs of certain conditions might be seen—or heard—in a person’s voice. “Accexible works […]
Read MoreThe Samsung Knox suite is one of the most secure platforms in the mobile industry, and the Korean tech giant revealed today that Knox is helping Bottneuro AG with its work on stopping the progression of Alzheimer’s disease. Samsung and Bottneuro partnered when Bottneuro AG spun off from the University of Basel in 2021. Although […]
Read MoreWatching the Alzheimer’s research world from the outside over the past two years has felt like a car ride over an unpaved mountain road without a seatbelt. In 2021, the US Food and Drug Administration took the unusual step of overruling its advisory committee to approve the sale of Aduhelm, the first new Alzheimer’s drug […]
Read More
